BioSpace News Archive

MediPharm Labs Corp. is pleased to announce it has now received $7.27 Million in gross cash proceeds from the settlement agreement announced on October 2, 2023 to resolve a claim in connection with a commercial agreement dispute.

C 2 N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology.

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, is pleased to announce its participation, in-person, at the Jefferies London Healthcare Conference and at McDermott Will & Emery’s Life Sciences Symposium.

ANGLE plc is pleased to announce the publication of a study using the Parsortix system that sheds new light on the phenotypic characteristics of CTCs in Head and Neck Squamous Cell Carcinoma.

Sosei Group Corporation will hold an R&D Day on Friday, 10 November 2023, at 4 pm JST. The meeting will be held virtually via Zoom webinar.

Visgenx, Inc., a biotechnology company focused on developing gene therapies for degenerative retinal diseases, announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,793,890, entitled “ELOVL2 Constructs for Human Gene Therapy”.

United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its third quarter 2023 financial results before the market opens on Wednesday, November 1, 2023.

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 8:00 a.m. ET.